Purpose: Randomized studies assessing the effect of PSA screening on mortality in non-Hispanic Black (NHB) men are lacking. We aimed to assess the association between PSA screening and survival among NHB men in comparison to non-Hispanic White (NHW) men in a racially diverse real-world North American population.
Materials And Methods: The study cohort included 6378 men who self-identified as NHB or NHW and were diagnosed with prostate cancer (PCa). Patients received PSA screening and subsequent PCa treatment and follow-up at our institution. Patients were sorted based on PSA testing intensity for the 5 years prior to diagnosis, as follows: never, some (<1 test/y), and annual testing (1 test/y). The primary outcome was risk of prostate cancer-specific mortality (PCSM). Competing risk cumulative incidence curves estimated PCSM rates. Competing risk regression analyses examined the impact of PSA testing on PCSM. An interaction term was incorporated to assess the impact of race on the outcome.
Results: Median (IQR) age and PSA at diagnosis were 67 (60-73) years and 5.8 (4.4-9.6) ng/mL, respectively, and 2929 (46%) men were NHB (Kruskal-Wallis values < .001). Annual PSA testing was more frequent in NHW (5%) than in NHB (3%) men (χ value < .001). On cumulative incidence analysis, in the never, some, and annual PSA testing groups, the 10-year PCSM was respectively 12.3%, 5.8%, and 4.6% in NHW and 18.5%, 7%, and 1.2% in NHB patients (Gray's test values < .001). At competing risk regression, PSA screening rate was associated with more favorable PCSM rates (HR: 0.47; 95% CI 0.33-0.68; < .001). The interaction term for race did not show statistical significance ( = .2).
Conclusions: PSA testing was associated with a reduced risk of PCSM in both NHB and NHW men diagnosed with PCa. Additionally, the positive impact of the screening rate seemed to be independent of race.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/JU.0000000000004118 | DOI Listing |
Semin Arthritis Rheum
December 2024
Department of Rheumatology and Joint and Bone Research Unit. Fundación Jiménez Díaz University Hospital and Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Autonomous University of Madrid, Madrid, Spain. Electronic address:
Purpose: The primary objective of this prospective, longitudinal, observational, single-centre study was to evaluate the association between ultrasound-assessed lesions of dactylitis and the diagnosis of psoriatic arthritis (PsA) in patients with psoriasis (PsO) and hand arthralgia.
Methods: We included adult patients diagnosed with PsO with hand arthralgia, with or without other musculoskeletal complaints. They were clinically assessed at baseline, 6 and 12 months by a rheumatologist blinded to the ultrasound findings.
Biosensors (Basel)
December 2024
Department of Chemical Engineering and Biotechnology, Graduate Institute of Biochemical and Biomedical Engineering, National Taipei University of Technology, Taipei City 10608, Taiwan.
In this study, we detected the expression levels of miR-21 in 38 clinical urine samples, obtained from 10 patients with PCa (with each sample obtained at three time points: before surgery, 1 month after surgery, and 3 months after surgery), 3 patients with benign prostatic hypertrophy (BPH), and 5 healthy subjects (as a control group). All of the samples were examined using a silver nanoparticle-based biosensor, and the sensitivity of the biosensor was simultaneously confirmed via qRT-PCR. The results were further analyzed together with clinical data such as PSA values and cancer stages.
View Article and Find Full Text PDFBiosensors (Basel)
December 2024
Center of Excellence for Trace Analysis and Biosensor, Prince of Songkla University, Hat Yai 90110, Thailand.
The activated carbon from marigold flowers (MG) was used to make an unlabeled electrochemical immunosensor to determine prostate cancer. MG was synthesized by hydrothermal carbonization and pyrolysis. MG had a large surface area, was highly conductive, and biocompatible.
View Article and Find Full Text PDFJ Pharm Technol
December 2024
Rheumatology Department, Hospital de Sagunto, Port de Sagunt, Spain.
Provide real-world data on switching from adalimumab biosimilar MSB11022 to GP2017 related to persistence, adherence, and safety in adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). Retrospective cohort study that used registries and medical records from a single hospital (June 2022 to April 2024). Adult patients with RA, PsA, and axSpA treated with adalimumab biosimilar MSB11022 who switched to biosimilar GP2017 were identified and followed up until April 2024, or disenrollment.
View Article and Find Full Text PDFCureus
November 2024
Urology, Peterborough City Hospital, Peterborough, GBR.
Introduction Prostate cancer remains the most prevalent cancer among men and continues to present a significant public health challenge globally. The disease's growing prevalence has heightened the demand for skilled professionals capable of obtaining histological samples for accurate diagnosis, as tissue biopsy remains the cornerstone for diagnosing prostate cancer. Surgical care practitioners have become integral to the surgical team, and their roles have expanded to include performing biopsies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!